2-(2,6-dioxopiperidin-3-yl)phthalimidine (EM 12)

thalidomide analog; structure; RN given refers to cpd without isomeric designation

Also Known As:

EM 12; 2-(2,6-dioxopiperidin-3-yl)phthalimidine, (+-)-isomer; 2-(2,6-dioxopiperidin-3-yl)phthalimidine, (R)-isomer; 2-(2,6-dioxopiperidin-3-yl)phthalimidine, (S)-isomer; 2-(2,6-dioxopiperidine-3-yl)phthalimidine; EM-12; 3-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione

Networked: 8 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Ayan Saatçioğlu, Şevin: 1 article (11/2020)
2.	Bingol, Ayhan: 1 article (11/2020)
3.	Erdogan, Gokcen: 1 article (11/2020)
4.	Ertem, Devrimsel Harika: 1 article (11/2020)
5.	Kokar, Serdar: 1 article (11/2020)
6.	Mercan, Özlem: 1 article (11/2020)
7.	Saglam, Hanife: 1 article (11/2020)
8.	Uluduz, Derya: 1 article (11/2020)
9.	Baumgartner, Scott: 1 article (01/2019)
10.	Dalbeth, Nicola: 1 article (01/2019)

Related Diseases

1.	Migraine Disorders (Migraine) 11/01/2020 - "In all, 18 sexually active patients with episodic migraine (EM), 12 patients with chronic migraine (CM), and 22 healthy controls of similar age were enrolled in the study. "
2.	Neoplasms (Cancer) 11/28/2018 - "We demonstrate that EM 12+, with a strong absorption (500-850 nm), efficiently quenches the fluorescence (580, 700, or 830 nm) of different fluorophores within 12+-SNPs, while the selective conversion into colorless diene 2 via H2S-mediated two-electron reduction significantly recovers fluorescence, allowing for non-invasive imaging of hepatic and tumor H2S in mice in real time. " 07/01/2016 - "O local do tumor primário foi o sistema colorretal em 46 doentes, o pulmão em 6, os tecidos moles em 4, o rim em 3 e outros tumores em 12. "
3.	Neurofibroma 11/01/2021 - "Achados associados incluíram neurofibromas cutâneos e subcutâneos em 12 pacientes (85,7%), opacidades em vidro fosco em um (7,1%) e neurofibromas traqueobrônquicos em um (7,1%). "
4.	Gout 01/01/2019 - "The adjusted mean (SE) rates of gout flares requiring treatment from the end of EM 2 to the end of EM 12 were 0.6 (0.19), 1.3 (0.48), 0.2 (0.08), and 1.9 (0.93), respectively. " 01/01/2019 - "The key secondary endpoint was mean rate of gout flares requiring treatment from the end of EM 2 to the end of EM 12. "
5.	Edema (Dropsy) 11/01/2022 - "Dezessete quadris foram analisados, identificando-se sinovite em 12 (70,6%), bursite trocantérica em 11 (64,7%), peritendinite em 17 (100%) e edema capsular em 14 (82,4%). "

Related Drugs and Biologics

1.	Thalidomide (Thalomid)
2.	azoxystrobin